1
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Condition(s):Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell LymphomaLast Updated:November 20, 2019Completed
Folotyn: 38 Clinical Trials, Page 1 of 4
Hide Studies Not Open or Pending
2
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition(s):Peripheral T-Cell Lymphoma (PTCL)Last Updated:July 27, 2021Completed
3
Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin’s Lymphoma Receiving Folotyn
Condition(s):Non Hodgkin’s LymphomaLast Updated:January 23, 2020Withdrawn
4
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy
Condition(s):Peripheral T Cell Lymphoma; Progression, DiseaseLast Updated:May 12, 2017Unknown status
5
Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Condition(s):Non-Small Cell Lung CancerLast Updated:January 23, 2020Withdrawn
6
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition(s):Cutaneous T-cell LymphomaLast Updated:January 3, 2020Completed
7
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Condition(s):Lymphoma, T-Cell, PeripheralLast Updated:December 19, 2018Withdrawn
8
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Condition(s):Advanced Cancers; Solid TumorsLast Updated:July 4, 2016Completed
9
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Condition(s):Refractory Peripheral T-Cell Lymphoma; Relapsed T-Cell LymphomaLast Updated:October 1, 2019Completed
10
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Condition(s):Lymphoid Malignancies; Multiple Myeloma; Lymphoma; Hodgkin Lymphoma; Non-hodgkin LymphomaLast Updated:February 7, 2020Unknown status